Inactive Instrument

OSPY MEDI CDI

Equities

OSP

AU000000OSP4

Osprey Medical, Inc. Appoints Martin Emerson to its Board of Directors

August 11, 2021 at 06:55 pm EDT

Osprey Medical, Inc. announced the appointment of Martin Emerson to its Board of Directors. With over 35 years of experience in the healthcare field and a track record of successes in market development, geographic expansion and existing market growth, Mr. Emerson is a welcome addition to the Osprey board. Mr. Emerson's extensive experience in healthcare include CEO positions in companies such as American Medical Systems, Galil Medical and his current position as the President and CEO of Monteris Medical. Mr. Emerson brings a depth of leadership experience in guiding organizations through commercial execution and value creation.

Latest news about OSPY MEDI CDI

Osprey Medical Restructures Business; Aims to Reduce Credit	22-06-01	MT
Osprey Medical, Inc. Announces Board Changes	22-05-25	CI
Osprey Medical, Inc. Auditor Raises 'Going Concern' Doubt	22-04-19	CI
Osprey Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-27	CI
Transcript : Osprey Medical, Inc., Q4 2021 Earnings Call, Jan 31, 2022	22-01-30
Dyevert Announces Highlighted by Leading Experts for Reduction of Aki	21-10-27	CI
Osprey Medical : Fiscal Q1 Global Revenue Jumps 34%; Shares Rise 6%	21-10-19	MT
Transcript : Osprey Medical, Inc. - Special Call	21-10-19
Transcript : Osprey Medical, Inc. - Shareholder/Analyst Call	21-09-02
Osprey Medical, Inc. Announces Executive Appointments	21-08-16	CI
Osprey Medical, Inc. Announces Earnings Results for the Half Year Ended June 30, 2021	21-08-16	CI
Osprey Medical : Appoints New Board Member	21-08-12	MT
Osprey Medical, Inc. Appoints Martin Emerson to its Board of Directors	21-08-11	CI
Transcript : Osprey Medical, Inc., Q2 2021 Earnings Call, Jul 29, 2021	21-07-28
Osprey Medical : Expands DyeVert Technology to Canada	21-07-20	MT
Osprey Signs an Exclusive Distribution Agreement with GE Healthcare Canada Inc	21-07-19	CI
Osprey Medical, Inc. Announces Appointment of Steven Brandt as Director	21-06-30	CI
Transcript : Osprey Medical, Inc. - Shareholder/Analyst Call	21-05-10
Transcript : Osprey Medical, Inc., Q1 2021 Earnings Call, Apr 22, 2021	21-04-21
Osprey Medical, Inc. Reports Revenue Results for the First Quarter of 2021	21-04-21	CI
Osprey Medical : Pushes Sales Coverage in US; Shares Jump 5%	21-03-18	MT
Osprey Medical, Inc. Sigs Independent Sales Agency Agreements with St Patrick's Distributing Inc	21-03-17	CI
Osprey Medical : Expands US Sales Coverage With Three Sales Agreements	21-03-02	MT
Osprey Medical, Inc. Signs Independent Sales Agency Agreements with Access Medical Inc., Consolidated Medical Supplies Inc. and Drikot Medical Inc	21-03-01	CI
Transcript : Osprey Medical, Inc., Q4 2020 Earnings Call, Jan 28, 2021	21-01-27

Chart OSPY MEDI CDI

Duration

Period

More charts

Company Profile

Osprey Medical, Inc. is a commercial stage company, which is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's products include AVERT, AVERT Plus, the DyeVert NG, DyeVert Plus, and DyeVert Plus EZ Systems. The AVERT Plus System reduces and monitors the amount of contrast dye used in commonly performed heart and peripheral vascular procedures. The DyeVert System is a self-adjusting product that reduces the amount of contrast dye used in commonly performed heart and peripheral procedures. DyeVert interfaces with syringe-manifold systems. These technologies are available with the United States Food and Drug Administration cleared indication for dye volume reduction. Its dye reduction and monitoring technologies are designed to help physicians minimize dye usage and reduce kidney damage associated with the use of contrast media for common cardiovascular procedures.

Sector

More about the company